West Cancer Center

LUNG: NSCLC: 1st Line: KRAS G12C mt: KRYSTAL-7

A Phase 2 Trial of MRTX849 in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Title

Mirati 847-007 (Lung 1st Line G12C)

Study Title

A Phase 2 Trial of MRTX849 in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Site Link

NCT04613596

Malignancy

Non small cell lung cancer (NSCLC)

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

1st Line

Investigational Agent

MRTX849 (adagrasib), Pembrolizumab

Drug Class

KRAS G12C inhibitor, PD-1 inhibitor

Jason Porter, MD

Sponsor

Mirati Therapeutics Inc.

Phase

Phase 2

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Histologically confirmed diagnosis of metastatic or unresectable NSCLC (squamous or nonsquamous) not a candidate for definitive therapy
KRAS G12C mutation
Known PD-L1 status (can enroll regardless of level)
1st line- no prior treatment for metastatic NSCLC
- OK to have had radiosensitizing chemo >1 year prior
ECOG PS 0-1
Measurable disease
No active CNS mets
No XRT to the lungs within 6 months prior to first dose of study treatment
No known autimmune disease

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Non-small cell lung cancer, KRAS G12C mutation

Dosing Frequency

Control Agents

Study Protocol

Randomized